Skip to main content

Advertisement

SpringerLink
Log in

Molecular Prognostic and Predictive Markers in Colorectal Cancer: Current Status

  • Published:
Current Colorectal Cancer Reports

Abstract

In parallel with our growing understanding of the molecular pathways underlying colorectal neoplasia, significant advances have been made in the treatment of colorectal cancer (CRC). For the past few decades, 5-fluorouracil-based therapy has been the cornerstone of adjuvant therapy. More recently, additional cytotoxic drugs and molecular-targeted therapies have provided additional clinical benefit in certain patient populations. Unfortunately, overall survival remains about 45%. Notably, our understanding of why certain patients do or do not respond to treatment remains limited. Thus, as therapeutic options for CRC continue to expand, there is now an even greater imperative to identify reliable biomarkers that have the potential to predict prognosis as well as response to chemotherapy. In this review, we will summarize the current status of such molecular prognostic and predictive biomarkers in CRC and assess their usefulness in tailoring therapeutic options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.

    Article  PubMed  Google Scholar 

  2. O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American joint committee on cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420–5.

    Article  PubMed  Google Scholar 

  3. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSCIA trial. J Clin Oncol. 2009;27:3109–16.

    Article  PubMed  CAS  Google Scholar 

  4. Goldberg RM. Therapy for metastatic colorectal cancer. Oncologist. 2006;11:981–7.

    Article  PubMed  CAS  Google Scholar 

  5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.

    Article  PubMed  CAS  Google Scholar 

  6. •• Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757–1765. This article demonstrated KRAS’ predictive value in patients with mCRC receiving cetuximab, an EGFR inhibitor.

    Article  PubMed  CAS  Google Scholar 

  7. Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.

    Article  Google Scholar 

  8. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–32.

    Article  PubMed  CAS  Google Scholar 

  9. • Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008; 135:1079–1099. This article is a comprehensive review of genetic and epigenetic changes that occur during CRC development and metastasis.

    Article  PubMed  CAS  Google Scholar 

  10. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.

    Article  PubMed  CAS  Google Scholar 

  11. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–18.

    Article  PubMed  CAS  Google Scholar 

  12. Tejpar S, Bosman F, Delorenzi M, et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETAC 3-EORTC 40993-SAKK60/00 trial). J Clin Oncol. 2009;27:15s. [Abstract: 4001]. Presented at the 2009 Annual Meeting of the ASCO. Orlando, Florida; May 29–June 2, 2009.

    Article  Google Scholar 

  13. •• Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28:3219–26. This article demonstrated dMMR’s prognostic value in stage II and III CRC.

    Article  PubMed  CAS  Google Scholar 

  14. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia group B protocol 89803. J Clin Oncol. 2009;27:1814–21.

    Article  PubMed  CAS  Google Scholar 

  15. Ogino S, Meyerhardt JA, Irahara N, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89802. Clin Cancer Res. 2009;15:7322–9.

    Article  PubMed  CAS  Google Scholar 

  16. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst. 1998;90:675–84.

    Article  PubMed  CAS  Google Scholar 

  17. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the “RASCAL II” study. Br J Cancer. 2001;85:692–6.

    Article  PubMed  CAS  Google Scholar 

  18. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. J Clin Oncol. 2010;28:466–74.

    Article  PubMed  CAS  Google Scholar 

  19. •• Amado RG, Wolf M, Peters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626–34. This article demonstrated KRAS’ predictive value in patients with mCRC receiving panitumumab, an EGFR inhibitor.

    Article  PubMed  CAS  Google Scholar 

  20. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Biomarkers predictive for outcome on patients with metastatic colorectal cancer treated with first-line FOLFOX4 plus or minus cetuximab: updated data from the OPUS study [Abstract: 428]. Presented at the 2010 Gastrointestinal Cancers Symposium. Orlando, Florida; January 22–24, 2010

  21. Kohne C, Stroiakovski D, Chang-chien C, et al. Predictive biomarkers to improve treatment of metastatic colorectal cancer; outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial. J Clin Oncol. 2009;27:15s. [Abstract: 4068]. Presented at the 2009 Annual Meeting of the ASCO. Orlando, Florida; May 29–June 2, 2009.

    Article  Google Scholar 

  22. Van Cutsem E, Rougier P, Kohne C, et al. A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy as 1st line treatment for patients with metastatic colorectal cancer: results according to KRAS and BRAF mutation status. Eur J Cancer. 2009;7:324. [Abstract: 6077]. Presented at the 2009 ECCO/ESMO Multidisciplinary Congress Meeting. Berlin, Germany; September 20–24, 2009.

    Google Scholar 

  23. Minoo P, Moyer MP, Jass JR. Role of BRAF-V600E in the serrated pathway of colorectal tumorigenesis. J Pathol. 2007;212:124–33.

    Article  PubMed  CAS  Google Scholar 

  24. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65:6063–9.

    Article  PubMed  CAS  Google Scholar 

  25. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatelite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;5858:90–6.

    Article  Google Scholar 

  26. Van Cutsem E, Lang G, Folprecht M, et al. Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. J Clin Oncol. 2010;28:15s. [Abstract: 3570]. Presented at the 2010 Annual Meeting of the ASCO. Chicago, Illinois; June 4–8, 2010.

    Google Scholar 

  27. Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer. 2005;41:2060–70.

    Article  PubMed  CAS  Google Scholar 

  28. Sun XF, Rutten S, Zhang H, et al. Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma. J Clin Oncol. 1999;17:1745–50.

    PubMed  CAS  Google Scholar 

  29. Watanabe T, Wu TT, Catalano PL, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344:1196–206.

    Article  PubMed  CAS  Google Scholar 

  30. Bertagnolli MM, Niedzwiecki D, Hall M, et al. Presence of 18q loss of heterozygosity (LOH) and disease free and overall survival in stage II colon cancer: CALGB Protocol 89803. J Clin Oncol. 2009;27:15s. [Abstract: 4012]. Presented at the 2009 Annual Meeting of the ASCO. Orlando, Florida; May 29–June 2, 2009.

    Article  Google Scholar 

  31. Russo A, Bazan V, Iacopetta B, et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutations: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 2005;23:7518–28.

    Article  PubMed  CAS  Google Scholar 

  32. Allegra CJ, Paik S, Colangelo LH, et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes’ B and C colon cancer: a national cancer institute-national surgical adjuvant breast and bowel project collaborative study. J Clin Oncol. 2003;21:241–50.

    Article  PubMed  CAS  Google Scholar 

  33. Westra JL, Schaapveld M, Hollema H, et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol. 2005;23:5635–43.

    Article  PubMed  CAS  Google Scholar 

  34. Popat S, Chen Z, Zhao D, et al. A prospective, blinded analysis of thymidylate synthase and p53 expression a prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol. 2006;17:1810–7.

    Article  PubMed  CAS  Google Scholar 

  35. Edler D, Glimelius B, Hallstrom M, et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol. 2002;20:1721–8.

    Article  PubMed  CAS  Google Scholar 

  36. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2004;22:529–36.

    Article  PubMed  CAS  Google Scholar 

  37. Soong R, Shah N, Salto-Tellez M, et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol. 2009;19:915–9.

    Article  Google Scholar 

  38. Johnston G, Fisher ER, Rockette HE, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol. 1994;12:2640–7.

    PubMed  CAS  Google Scholar 

  39. Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. Postgrad Med J. 2008;84:403–11.

    Article  PubMed  CAS  Google Scholar 

  40. El-Khoueiry A, Pohl A, Danenberg K, et al. Wt Kras and gene expression levels of VEGFR2, EGFR, and ERCC-1 associated with progression-free survival (PFS) in patients with metastatic colorectal cancer treated with first line 5-FU or capecitabine with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV). J Clin Oncol. 2009;27:15s. [Abstract: 4056]. Presented at the 2009 Annual Meeting of the ASCO. Orlando, Florida; May 29–June 2, 2009.

    Article  Google Scholar 

  41. Soumaoro LT, Uetake H, Higuchi T, et al. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004;10:8465–71.

    Article  PubMed  CAS  Google Scholar 

  42. Ogino S, Kirkner GJ, Nosho K, et al. Cyclooxygenase-2 is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res. 2008;14:8221–7.

    Article  PubMed  CAS  Google Scholar 

  43. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302:649–58.

    Article  PubMed  CAS  Google Scholar 

  44. Ogino S, Nosho K, Kirkner GJ, et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst. 2008;100:1734–8.

    Article  PubMed  CAS  Google Scholar 

  45. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology. 2010;138:2029–43.

    Article  PubMed  CAS  Google Scholar 

  46. Ogino S, Nosho K, Meyerhardt JA, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008;26:5713–20.

    Article  PubMed  CAS  Google Scholar 

  47. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes’ B colon cancer. J Clin Oncol. 2004;22:1564–71.

    Article  PubMed  CAS  Google Scholar 

  48. Smith JJ, Deane NG, Wu F, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 2010;138:958–68.

    Article  PubMed  CAS  Google Scholar 

  49. O’Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010;28:3937–44.

    Article  PubMed  Google Scholar 

  50. Tomlinson IP, Webb E, Carvajal-Carmona L. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosome 10p14 and 8q23.3. Nat Genet. 2008;40:623–30.

    Article  PubMed  CAS  Google Scholar 

  51. Tenesa A, Theodoratou E, Din FV, et al. Ten common genetic variants associated with colorectal cancer risk are not associated with survival after diagnosis. Clin Cancer Res. 2010;16:3754–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. U.C. San Diego Department of Medicine, 200 W. Arbor Drive, San Diego, CA, 92103, USA

    Jeffrey K. Lee

  2. Massachusetts General Hospital, Gastrointestinal Unit, 55 Fruit Street, GRJ-722, Boston, MA, 02114, USA

    Andrew T. Chan

Authors
  1. Jeffrey K. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew T. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew T. Chan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, J.K., Chan, A.T. Molecular Prognostic and Predictive Markers in Colorectal Cancer: Current Status. Curr Colorectal Cancer Rep 7, 136–144 (2011). https://doi.org/10.1007/s11888-011-0091-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-011-0091-4

Keywords

Search

Navigation